| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.099 | 0.1 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.075 | 0.1 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.11 | 0.1 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.1 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |